Undiscovered Gems In India Top 3 Stocks To Watch This September 2024
In This Article:
In the last week, the Indian market has risen by 1.7%, and over the past year, it has climbed an impressive 41%, with earnings forecasted to grow by 17% annually. In this robust environment, identifying stocks with strong growth potential and solid fundamentals can be particularly rewarding for investors looking to capitalize on India's dynamic market.
Top 10 Undiscovered Gems With Strong Fundamentals In India
| Name | Debt To Equity | Revenue Growth | Earnings Growth | Health Rating |
|---|---|---|---|---|
| Shree Digvijay Cement | 0.01% | 13.97% | 16.37% | ★★★★★★ |
| Wealth First Portfolio Managers | NA | -47.95% | 40.47% | ★★★★★★ |
| AGI Infra | 61.29% | 29.16% | 33.44% | ★★★★★★ |
| Network People Services Technologies | 0.24% | 81.82% | 86.35% | ★★★★★☆ |
| Kaycee Industries | 17.35% | 19.50% | 34.62% | ★★★★★☆ |
| Insolation Energy | 88.64% | 163.87% | 419.31% | ★★★★★☆ |
| JSW Holdings | NA | 21.35% | 22.41% | ★★★★★☆ |
| Innovana Thinklabs | 13.59% | 12.51% | 20.01% | ★★★★☆☆ |
| SG Mart | 16.77% | 98.09% | 96.54% | ★★★★☆☆ |
| Abans Holdings | 91.77% | 13.13% | 18.72% | ★★★★☆☆ |
We'll examine a selection from our screener results.
Advanced Enzyme Technologies
Simply Wall St Value Rating: ★★★★★★
Overview: Advanced Enzyme Technologies Limited, together with its subsidiaries, engages in the research, development, manufacture, and marketing of enzymes and probiotics in India, Europe, the United States, Asia, and internationally with a market cap of ?59.63 billion.
Operations: The primary revenue stream for Advanced Enzyme Technologies is the manufacturing and sales of enzymes, generating ?6.31 billion.
Advanced Enzyme Technologies, a promising player in the enzyme sector, has seen its debt to equity ratio drop from 5% to 3.5% over five years. The company reported Q1 2024 net income of INR 341.52 million, up from INR 288.1 million last year. Earnings per share rose to INR 3.05 from INR 2.58 previously, reflecting solid performance despite significant insider selling recently observed and earnings growth of nearly double the industry average at 18.9%.
Marksans Pharma
Simply Wall St Value Rating: ★★★★★★
Overview: Marksans Pharma Limited, with a market cap of ?125.82 billion, is involved in the research, manufacturing, marketing, and sale of pharmaceutical formulations across various international markets including the United States, North America, Europe, the United Kingdom, Australia, and New Zealand.
Operations: Marksans Pharma Limited generates revenue primarily from its pharmaceutical formulations segment, amounting to ?22.68 billion. The company's net profit margin is a key indicator of its profitability.